vTv Therapeutics reports Q1 net income of $24.1M on $36.8M license revenue; CATT1 enrollment on track

vTv Therapeutics Inc.

Net income attributable to shareholders of $24.1M ($1.94 basic EPS) vs. net loss of $5.1M a year ago.
Revenue of $36.8M from Newsoara license amendment; $20M upfront plus up to ~$115M milestones.
Cash $98.1M at March 31, 2026, up from $88.9M; company says funds through CATT1 topline readout.
Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes — enrollment on track for completion in Q3 2026.
R&D expenses $9.0M (vs. $2.8M) driven by CATT1 trial investment; G&A $4.6M (vs. $3.7M).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.